All approved drugs for Alzheimer disease (AD) in clinical practice ameliorate the symptoms of the disease. Among them, acetylcholinesterase inhibitors (AChEIs) are used to increase the cholinergic activity. Among new AChEI, tacrine compounds were found to be more toxic compared to 7-MEOTA (9-amino-7-methoxy-1,2,3,4-tetrahydroacridine). In this Letter, series of 7-MEOTA analogues (N-alkyl-7-methoxytacrine) were synthesized. Their inhibitory ability was evaluated on recombinant human acetylcholinesterase (AChE) and plasmatic human butyrylcholinesterase (BChE). Three novel compounds showed promising results towards hAChE better to THA or 7-MEOTA. Three compounds resulted as potent inhibitors of hBChE. The SAR findings highlighted the C(6)-C(7)N-alkyl chains for cholinesterase inhibition.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.08.044DOI Listing

Publication Analysis

Top Keywords

alzheimer disease
8
synthesis vitro
4
vitro evaluation
4
evaluation n-alkyl-7-methoxytacrine
4
n-alkyl-7-methoxytacrine hydrochlorides
4
hydrochlorides potential
4
potential cholinesterase
4
cholinesterase inhibitors
4
inhibitors alzheimer
4
disease approved
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!